Aligos Therapeutics Inc Market Cap ($25.59 Million)
Market Cap & Net Worth: Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics Inc market cap. Aligos Therapeutics Inc (NASDAQ:ALGS) has a market capitalization of $25.59 Million ($25.59 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24123 globally and #5216 in its home market, demonstrating a 2.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aligos Therapeutics Inc's stock price $4.75 by its total outstanding shares 5388223 (5.39 Million). Also see cash efficiency ratio of Aligos Therapeutics Inc for how efficiently the company converts equity into cash flow.
Aligos Therapeutics Inc Market Cap History (2020–2026)
Aligos Therapeutics Inc market cap history from 2020 to 2026. Data shows change from $3.72 Billion to $25.59 Million (-51.33% CAGR). Check Aligos Therapeutics Inc (ALGS) share price today for real-time trading data and today's change.
Index Memberships
Aligos Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #683 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2251 of 3165 |
Weight: Aligos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aligos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aligos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Aligos Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
22.97x
Aligos Therapeutics Inc's market cap is 22.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.72 Billion | $-10.55 Million | -$108.54 Million | -353.11x | N/A |
| 2021 | $1.60 Billion | $4.36 Million | -$128.33 Million | 366.82x | N/A |
| 2022 | $128.37 Million | $13.91 Million | -$96.05 Million | 9.23x | N/A |
| 2023 | $89.44 Million | $15.53 Million | -$87.68 Million | 5.76x | N/A |
| 2024 | $214.67 Million | $3.94 Million | -$131.21 Million | 54.41x | N/A |
| 2025 | $50.22 Million | $2.19 Million | -$24.19 Million | 22.97x | N/A |
Competitor Companies of ALGS by Market Capitalization
Companies near Aligos Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see ALGS asset base for a full breakdown of the balance sheet.
Key companies related to Aligos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Aligos Therapeutics Inc (2020–2026)
Market capitalization of Aligos Therapeutics Inc from 2020 to today. Between 2020 and today, Aligos Therapeutics Inc's market cap moved from $3.72 Billion to $ 25.59 Million, with a yearly change of -51.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.59 Million | -49.03% |
| 2025 | $50.22 Million | -76.61% |
| 2024 | $214.67 Million | +140.00% |
| 2023 | $89.44 Million | -30.33% |
| 2022 | $128.37 Million | -91.97% |
| 2021 | $1.60 Billion | -57.07% |
| 2020 | $3.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Aligos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.59 Million USD |
| MoneyControl | $25.59 Million USD |
| MarketWatch | $25.59 Million USD |
| marketcap.company | $25.59 Million USD |
| Reuters | $25.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more